EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Survival outcomes in dogs treated with vinorelbine‐based adjuvant treatment following surgical resection of grade II and III pulmonary carcinoma

N Wong iD, L Brockley iD, S Rajan, J Yu iD

Journal of Small Animal Practice · 04.08.2026

DOI: 10.1111/jsap.70183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Small Animal Practice, online erschienen am 04.08.2026. Verfasst von N Wong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Animal Referral Hospital Canberra, Pialligo, Australian Capital Territory, Australia. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Pulmonary carcinoma in dogs is commonly managed with surgical resection; however, the role of adjuvant chemotherapy for grade II and III carcinomas remains unclear. This retrospective multicentre study investigated the outcomes in dogs treated with vinorelbine‐based adjuvant treatment (as monotherapy or combined chemotherapy) following surgical resection, compared to surgical resection alone. Materials and Methods Fifty‐six dogs with histologically confirmed grade II and III pulmonary carcinoma were evaluated in this study. Thirty‐six dogs received vinorelbine‐based adjuvant treatment post‐surgery based on owner decision following consultation with a veterinary oncologist. Twenty dogs underwent surgical resection alone. The progression‐free survival and overall survival were assessed using Cox proportional hazards analysis.

Results

The median progression‐free survival was longer in dogs treated with vinorelbine‐based adjuvant treatment (232 days, 95% CI 137 to 385 days) compared to dogs treated with surgical resection only (124 days, 95% CI 36 to 220 days) (HR 0.39, 95% CI 0.21 to 0.70, P = .003). The median overall survival was longer in dogs treated with vinorelbine‐based adjuvant treatment (316 days, 95% CI 180 to 457 days) compared to dogs treated with surgical resection only (124 days, 95% CI 43 to 256 days) (HR 0.31, 95% CI 0.17 to 0.58, P < .001). The use of vinorelbine‐based adjuvant treatment and tumour grade were independent predictors of progression‐free survival and survival ( P < .001). Clinical Significance These findings suggest that vinorelbine‐based adjuvant treatment is associated with longer progression‐free survival and overall survival in dogs with grade II and III pulmonary carcinoma following surgical resection in this cohort. However, the variability in treatment protocols used in this study limits our ability to draw definitive conclusions regarding treatment efficacy.

Autor:innen und Institutionen

  • Animal Referral Hospital Canberra, Pialligo, Australian Capital Territory, Australia.
  • Advanced Vetcare, Kensington, Victoria, Australia.
  • Faculty of Science, Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria, Australia.
  • Department of Veterinary Clinical Sciences, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Kowloon Tong, Hong Kong, China.

ORCID-Profile: N Wong, L Brockley, J Yu

Zitieren

APA

Wong, N., Brockley, L., Rajan, S., & Yu, J. (2026). Survival outcomes in dogs treated with vinorelbine‐based adjuvant treatment following surgical resection of grade II and III pulmonary carcinoma. Journal of Small Animal Practice. https://doi.org/10.1111/jsap.70183

Vancouver

Wong N, Brockley L, Rajan S, Yu J. Survival outcomes in dogs treated with vinorelbine‐based adjuvant treatment following surgical resection of grade II and III pulmonary carcinoma. Journal of Small Animal Practice. 2026. doi:10.1111/jsap.70183

BibTeX
@article{Wong2026,
  author = {Wong, N and Brockley, L and Rajan, S and Yu, J},
  title = {Survival outcomes in dogs treated with vinorelbine‐based adjuvant treatment following surgical resection of grade II and III pulmonary carcinoma},
  journal = {Journal of Small Animal Practice},
  year = {2026},
  doi = {10.1111/jsap.70183}
}
Kostenlos starten →